TREMFYA

TREMFYA® is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis.

Administration and Dosage:

Ulcerative Colitis:

  • Induction:

    • 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8.

  • Maintenance:

    • 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter.

    • Or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter.

    • Use the lowest effective recommended dosage to maintain therapeutic response.

Common Side Effects:

The most common side effects of TREMFYA include:

  • Respiratory Tract Infections

  • Headache

  • Injection Site Reactions

  • Joint Pain (Arthralgia)

  • Diarrhea

  • Stomach Flu (Gastroenteritis)

  • Fungal Skin Infections

  • Herpes Simplex Infections

  • Bronchitis

These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

More information:

Please read the full Prescribing Information and Patient Information for TEPEZZA® and discuss any questions you have with your doctor.

Indication:

TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with:

  • Moderately to severely active ulcerative colitis (1.3)

Contact Us

Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!

Check our Privacy Practice